Abstract
BackgroundThe prevalence of depression in people receiving haemodialysis is high with estimates varying between 20 and 40 %. There is little research on the effectiveness of antidepressants in dialysis patients with the few clinical trials suffering significant methodological issues. We plan to carry out a study to evaluate the feasibility of conducting a randomised controlled trial in patients on haemodialysis who have diagnosed Major Depressive Disorder.Methods/DesignThe study has two phases, a screening phase and the randomised controlled trial. Patients will be screened initially with the Beck Depression Inventory to estimate the number of patients who score 16 or above. These patients will be invited to an interview with a psychiatrist who will invite those with a diagnosis of Major Depressive Disorder to take part in the trial. Consenting patients will be randomised to either Sertraline or placebo. Patients will be followed-up for 6 months.Demographic and clinical data will be collected at screening interview, baseline interview and 2 weeks, and every month (up to 6 months) after baseline. The primary outcome is to evaluate the feasibility of conducting a randomised, double blind, placebo pilot trial in haemodialysis patients with depression. Secondary outcomes include estimation of the variability in the outcome measures for the treatment and placebo arms, which will allow for a future adequately powered definitive trial. Analysis will primarily be descriptive, including the number of patients eligible for the trial, drug exposure of Sertraline in haemodialysis patients and the patient experience of participating in this trial.DiscussionThere is an urgent need for this research in the dialysis population because of the dearth of good quality and adequately powered studies. Research with renal patients is particularly difficult as they often have complex medical needs. This research will therefore not only assess the outcome of anti-depressants in haemodialysis patients with depression but also the process of running a randomised controlled trial in this population. Hence, the outputs of this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to determine the efficacy of anti-depressants in patient on haemodialysis with depression.Trial registrationISRCTN registry ISRCTN06146268 and EudraCT reference: 2012-000547-27.
Highlights
The prevalence of depression in people receiving haemodialysis is high with estimates varying between 20 and 40 %
This research will assess the outcome of anti-depressants in haemodialysis patients with depression and the process of running a randomised controlled trial in this population. The outputs of this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to determine the efficacy of anti-depressants in patient on haemodialysis with depression
The assumptions on which this estimate is based are: 30 % of patients will screen positive on the BDI-II [22] and that approximately 50 % of those patients will be subsequently be diagnosed with Major Depressive Disorder (MDD) following a psychiatric interview and that 50 % will agree to take part on the Trial Outcomes phase – e.g. 7.5 % of the sampled patients
Summary
The prevalence of depression in people receiving haemodialysis is high with estimates varying between 20 and 40 %. The prevalence of people receiving renal replacement therapy (RRT) for end stage renal disease (ESRD) is increasing worldwide. In the UK around 900 people per million were receiving these therapies in 2013, with approximately equal numbers on dialysis and transplantation [1]. These numbers continue to increase by about 4 % annually. People on dialysis have a high symptom burden and a greatly increased mortality [2, 3]. Attempts to identify feasible and effective treatments for depression in this setting remain a clinical priority
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.